The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer

HR+ Advanced Breast Cancer Introduction

Restaging at Relapse vs De Novo Metastatic Disease

Visceral Crisis

Personalizing Endocrine Therapy

Endocrine Therapy Landscape

FIRST Trial Fulvestrant vs Anastrozole

FIRST Trial -- Safety

FALCON: Anastrozole vs Fulvestrant in HR+ Advanced or Metastatic Breast Cancer

FALCON Most Common AEs (> 5%)

Aromatase Inhibitors Management of AEs

HOPE Study Exercise Adherence

Overcoming Endocrine Resistance in MBC

PALOMA-2 Palbociclib + Letrozole vs Letrozole Alone

PALOMA-2 AE Summary

Palbociclib Dosing and Drug Interaction

Palbociclib Management of Hematological Toxicities

MONALEESA-2: Ribociclib + Letrozole vs Letrozole in HR+ Advanced Breast Cancer

MONALEESA-2 Safety Profile

Managing Treatment-Related Adverse Events from CDK Inhibitors

BOLERO-2 Everolimus + Exemestane vs Placebo + Exemestane

BOLERO-2 Most Common Grade 3/4 Adverse Events

SWISH Trial Dexamethasone-Based Mouthwash for Stomatitis

Management Issues With Everolimus

PALOMA-3 Palbociclib + Fulvestrant in Pre/Perimenopausal MBC

PALOMA-3 Safety Results

Educating our patients

Managing Adherence to Oral Therapy

Specific Measures To Manage Patients

Concluding Remarks

Abbreviations

Abbreviations (cont)